Infliximab: a new therapeutic agent in acute pancreatitis?
Tumor necrosis factor alpha (TNF-alpha) has a central role in the pathogenesis of acute pancreatitis and related systemic complications. The aim of this study is to investigate the therapeutic effectiveness of monoclonal TNF antibody (infliximab) in acute edematous and severe necrotizing pancreatiti...
Gespeichert in:
| Veröffentlicht in: | Pancreas 2004-01, Vol.28 (1), p.e1-e8 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e8 |
|---|---|
| container_issue | 1 |
| container_start_page | e1 |
| container_title | Pancreas |
| container_volume | 28 |
| creator | Oruc, Nevin Ozutemiz, A Omer Yukselen, Vahit Nart, Deniz Celik, Handan Ak Yuce, Gul Batur, Yucel |
| description | Tumor necrosis factor alpha (TNF-alpha) has a central role in the pathogenesis of acute pancreatitis and related systemic complications. The aim of this study is to investigate the therapeutic effectiveness of monoclonal TNF antibody (infliximab) in acute edematous and severe necrotizing pancreatitis models in rats.
One hundred rats were randomly divided into 10 groups. Acute edematous pancreatitis (AEP) was induced by injection of cerulein 20 microg/kg 4 times subcutaneously at hourly intervals. Severe necrotizing pancreatitis (SNP) was induced by retrograde injection of 3% taurocholate into the common biliopancreatic duct. Infliximab 8 mg/kg was given via intravenous infusion. Serum amylase activity, pancreatic histopathology, myeloperoxidase enzyme activity (MPO), and pulmonary changes were assessed.
Infliximab treatment significantly decreased serum amylase activity (11939 +/- 1914 U/L versus 3458 +/- 915 U/L, P < 0.001) and histopathologic score (4.1 +/- 0.5 versus 1.5 +/- 0.3, P < 0.001) in AEP. It also suppressed neutrophil infiltration and MPO activity of the pancreatic tissue. In SNP, infliximab treatment was found to decrease pathologic score (9.4 +/- 1.2 versus 3.6 +/- 0.8, P < 0.001) and serum amylase activity (20442 +/- 2375 versus 8990 +/- 1730, P < 0.01). It ameliorated both parenchymal and fatty tissue necrosis of the pancreas. Infliximab also alleviated alveolar edema and acute respiratory distress syndrome like pulmonary complications, but the difference was not significant.
Chimeric TNF antibody, infliximab, should be evaluated for treatment of acute pancreatitis. |
| doi_str_mv | 10.1097/00006676-200401000-00020 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00006676_200401000_00020</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>14707742</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-39d2b808da9c1bec81824cc4e52805e2adad0f20daf39ffa0c678ee6bc06c27b3</originalsourceid><addsrcrecordid>eNpFkN1KxDAQRoMobl19BckLRCdJm6R7I7L4s7DgjV6XaTrRym4tTYr69lZ31YFh-C7OMHMY4xIuJJT2EqYyxhqhAHKQUxJTKzhgmSy0EblT7pBl4FwhtLR2xk5ifAWQVhflMZvJ3IK1ucrYYtWFTfvRbrFecOQdvfP0QgP2NKbWc3ymLvG24-jHRLzHzg-EqU1tvDplRwE3kc72c86ebm8el_di_XC3Wl6vhVeFSUKXjaoduAZLL2vyTjqVe59ToRwUpLDBBoKCBoMuQ0DwxjoiU3swXtlaz5nb7fXDW4wDhaofpnuHz0pC9a2j-tVR_emofnRM6PkO7cd6S80_uP9ffwEByFsn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Infliximab: a new therapeutic agent in acute pancreatitis?</title><source>MEDLINE</source><source>Journals@Ovid Ovid Autoload</source><creator>Oruc, Nevin ; Ozutemiz, A Omer ; Yukselen, Vahit ; Nart, Deniz ; Celik, Handan Ak ; Yuce, Gul ; Batur, Yucel</creator><creatorcontrib>Oruc, Nevin ; Ozutemiz, A Omer ; Yukselen, Vahit ; Nart, Deniz ; Celik, Handan Ak ; Yuce, Gul ; Batur, Yucel</creatorcontrib><description>Tumor necrosis factor alpha (TNF-alpha) has a central role in the pathogenesis of acute pancreatitis and related systemic complications. The aim of this study is to investigate the therapeutic effectiveness of monoclonal TNF antibody (infliximab) in acute edematous and severe necrotizing pancreatitis models in rats.
One hundred rats were randomly divided into 10 groups. Acute edematous pancreatitis (AEP) was induced by injection of cerulein 20 microg/kg 4 times subcutaneously at hourly intervals. Severe necrotizing pancreatitis (SNP) was induced by retrograde injection of 3% taurocholate into the common biliopancreatic duct. Infliximab 8 mg/kg was given via intravenous infusion. Serum amylase activity, pancreatic histopathology, myeloperoxidase enzyme activity (MPO), and pulmonary changes were assessed.
Infliximab treatment significantly decreased serum amylase activity (11939 +/- 1914 U/L versus 3458 +/- 915 U/L, P < 0.001) and histopathologic score (4.1 +/- 0.5 versus 1.5 +/- 0.3, P < 0.001) in AEP. It also suppressed neutrophil infiltration and MPO activity of the pancreatic tissue. In SNP, infliximab treatment was found to decrease pathologic score (9.4 +/- 1.2 versus 3.6 +/- 0.8, P < 0.001) and serum amylase activity (20442 +/- 2375 versus 8990 +/- 1730, P < 0.01). It ameliorated both parenchymal and fatty tissue necrosis of the pancreas. Infliximab also alleviated alveolar edema and acute respiratory distress syndrome like pulmonary complications, but the difference was not significant.
Chimeric TNF antibody, infliximab, should be evaluated for treatment of acute pancreatitis.</description><identifier>ISSN: 0885-3177</identifier><identifier>EISSN: 1536-4828</identifier><identifier>DOI: 10.1097/00006676-200401000-00020</identifier><identifier>PMID: 14707742</identifier><language>eng</language><publisher>United States</publisher><subject>Acute Disease ; Amylases - blood ; Animals ; Antibodies, Monoclonal - therapeutic use ; Ceruletide ; Edema - chemically induced ; Edema - drug therapy ; Infliximab ; Male ; Necrosis ; Pancreas - drug effects ; Pancreas - metabolism ; Pancreas - pathology ; Pancreatitis - chemically induced ; Pancreatitis - drug therapy ; Pancreatitis - pathology ; Pancreatitis, Acute Necrotizing - chemically induced ; Pancreatitis, Acute Necrotizing - drug therapy ; Pancreatitis, Acute Necrotizing - pathology ; Peroxidase - metabolism ; Pulmonary Edema - pathology ; Pulmonary Edema - prevention & control ; Rats ; Rats, Wistar ; Severity of Illness Index ; Taurocholic Acid ; Treatment Outcome ; Tumor Necrosis Factor-alpha - therapeutic use</subject><ispartof>Pancreas, 2004-01, Vol.28 (1), p.e1-e8</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-39d2b808da9c1bec81824cc4e52805e2adad0f20daf39ffa0c678ee6bc06c27b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14707742$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oruc, Nevin</creatorcontrib><creatorcontrib>Ozutemiz, A Omer</creatorcontrib><creatorcontrib>Yukselen, Vahit</creatorcontrib><creatorcontrib>Nart, Deniz</creatorcontrib><creatorcontrib>Celik, Handan Ak</creatorcontrib><creatorcontrib>Yuce, Gul</creatorcontrib><creatorcontrib>Batur, Yucel</creatorcontrib><title>Infliximab: a new therapeutic agent in acute pancreatitis?</title><title>Pancreas</title><addtitle>Pancreas</addtitle><description>Tumor necrosis factor alpha (TNF-alpha) has a central role in the pathogenesis of acute pancreatitis and related systemic complications. The aim of this study is to investigate the therapeutic effectiveness of monoclonal TNF antibody (infliximab) in acute edematous and severe necrotizing pancreatitis models in rats.
One hundred rats were randomly divided into 10 groups. Acute edematous pancreatitis (AEP) was induced by injection of cerulein 20 microg/kg 4 times subcutaneously at hourly intervals. Severe necrotizing pancreatitis (SNP) was induced by retrograde injection of 3% taurocholate into the common biliopancreatic duct. Infliximab 8 mg/kg was given via intravenous infusion. Serum amylase activity, pancreatic histopathology, myeloperoxidase enzyme activity (MPO), and pulmonary changes were assessed.
Infliximab treatment significantly decreased serum amylase activity (11939 +/- 1914 U/L versus 3458 +/- 915 U/L, P < 0.001) and histopathologic score (4.1 +/- 0.5 versus 1.5 +/- 0.3, P < 0.001) in AEP. It also suppressed neutrophil infiltration and MPO activity of the pancreatic tissue. In SNP, infliximab treatment was found to decrease pathologic score (9.4 +/- 1.2 versus 3.6 +/- 0.8, P < 0.001) and serum amylase activity (20442 +/- 2375 versus 8990 +/- 1730, P < 0.01). It ameliorated both parenchymal and fatty tissue necrosis of the pancreas. Infliximab also alleviated alveolar edema and acute respiratory distress syndrome like pulmonary complications, but the difference was not significant.
Chimeric TNF antibody, infliximab, should be evaluated for treatment of acute pancreatitis.</description><subject>Acute Disease</subject><subject>Amylases - blood</subject><subject>Animals</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Ceruletide</subject><subject>Edema - chemically induced</subject><subject>Edema - drug therapy</subject><subject>Infliximab</subject><subject>Male</subject><subject>Necrosis</subject><subject>Pancreas - drug effects</subject><subject>Pancreas - metabolism</subject><subject>Pancreas - pathology</subject><subject>Pancreatitis - chemically induced</subject><subject>Pancreatitis - drug therapy</subject><subject>Pancreatitis - pathology</subject><subject>Pancreatitis, Acute Necrotizing - chemically induced</subject><subject>Pancreatitis, Acute Necrotizing - drug therapy</subject><subject>Pancreatitis, Acute Necrotizing - pathology</subject><subject>Peroxidase - metabolism</subject><subject>Pulmonary Edema - pathology</subject><subject>Pulmonary Edema - prevention & control</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Severity of Illness Index</subject><subject>Taurocholic Acid</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - therapeutic use</subject><issn>0885-3177</issn><issn>1536-4828</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkN1KxDAQRoMobl19BckLRCdJm6R7I7L4s7DgjV6XaTrRym4tTYr69lZ31YFh-C7OMHMY4xIuJJT2EqYyxhqhAHKQUxJTKzhgmSy0EblT7pBl4FwhtLR2xk5ifAWQVhflMZvJ3IK1ucrYYtWFTfvRbrFecOQdvfP0QgP2NKbWc3ymLvG24-jHRLzHzg-EqU1tvDplRwE3kc72c86ebm8el_di_XC3Wl6vhVeFSUKXjaoduAZLL2vyTjqVe59ToRwUpLDBBoKCBoMuQ0DwxjoiU3swXtlaz5nb7fXDW4wDhaofpnuHz0pC9a2j-tVR_emofnRM6PkO7cd6S80_uP9ffwEByFsn</recordid><startdate>200401</startdate><enddate>200401</enddate><creator>Oruc, Nevin</creator><creator>Ozutemiz, A Omer</creator><creator>Yukselen, Vahit</creator><creator>Nart, Deniz</creator><creator>Celik, Handan Ak</creator><creator>Yuce, Gul</creator><creator>Batur, Yucel</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200401</creationdate><title>Infliximab: a new therapeutic agent in acute pancreatitis?</title><author>Oruc, Nevin ; Ozutemiz, A Omer ; Yukselen, Vahit ; Nart, Deniz ; Celik, Handan Ak ; Yuce, Gul ; Batur, Yucel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-39d2b808da9c1bec81824cc4e52805e2adad0f20daf39ffa0c678ee6bc06c27b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Acute Disease</topic><topic>Amylases - blood</topic><topic>Animals</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Ceruletide</topic><topic>Edema - chemically induced</topic><topic>Edema - drug therapy</topic><topic>Infliximab</topic><topic>Male</topic><topic>Necrosis</topic><topic>Pancreas - drug effects</topic><topic>Pancreas - metabolism</topic><topic>Pancreas - pathology</topic><topic>Pancreatitis - chemically induced</topic><topic>Pancreatitis - drug therapy</topic><topic>Pancreatitis - pathology</topic><topic>Pancreatitis, Acute Necrotizing - chemically induced</topic><topic>Pancreatitis, Acute Necrotizing - drug therapy</topic><topic>Pancreatitis, Acute Necrotizing - pathology</topic><topic>Peroxidase - metabolism</topic><topic>Pulmonary Edema - pathology</topic><topic>Pulmonary Edema - prevention & control</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Severity of Illness Index</topic><topic>Taurocholic Acid</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oruc, Nevin</creatorcontrib><creatorcontrib>Ozutemiz, A Omer</creatorcontrib><creatorcontrib>Yukselen, Vahit</creatorcontrib><creatorcontrib>Nart, Deniz</creatorcontrib><creatorcontrib>Celik, Handan Ak</creatorcontrib><creatorcontrib>Yuce, Gul</creatorcontrib><creatorcontrib>Batur, Yucel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Pancreas</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oruc, Nevin</au><au>Ozutemiz, A Omer</au><au>Yukselen, Vahit</au><au>Nart, Deniz</au><au>Celik, Handan Ak</au><au>Yuce, Gul</au><au>Batur, Yucel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infliximab: a new therapeutic agent in acute pancreatitis?</atitle><jtitle>Pancreas</jtitle><addtitle>Pancreas</addtitle><date>2004-01</date><risdate>2004</risdate><volume>28</volume><issue>1</issue><spage>e1</spage><epage>e8</epage><pages>e1-e8</pages><issn>0885-3177</issn><eissn>1536-4828</eissn><abstract>Tumor necrosis factor alpha (TNF-alpha) has a central role in the pathogenesis of acute pancreatitis and related systemic complications. The aim of this study is to investigate the therapeutic effectiveness of monoclonal TNF antibody (infliximab) in acute edematous and severe necrotizing pancreatitis models in rats.
One hundred rats were randomly divided into 10 groups. Acute edematous pancreatitis (AEP) was induced by injection of cerulein 20 microg/kg 4 times subcutaneously at hourly intervals. Severe necrotizing pancreatitis (SNP) was induced by retrograde injection of 3% taurocholate into the common biliopancreatic duct. Infliximab 8 mg/kg was given via intravenous infusion. Serum amylase activity, pancreatic histopathology, myeloperoxidase enzyme activity (MPO), and pulmonary changes were assessed.
Infliximab treatment significantly decreased serum amylase activity (11939 +/- 1914 U/L versus 3458 +/- 915 U/L, P < 0.001) and histopathologic score (4.1 +/- 0.5 versus 1.5 +/- 0.3, P < 0.001) in AEP. It also suppressed neutrophil infiltration and MPO activity of the pancreatic tissue. In SNP, infliximab treatment was found to decrease pathologic score (9.4 +/- 1.2 versus 3.6 +/- 0.8, P < 0.001) and serum amylase activity (20442 +/- 2375 versus 8990 +/- 1730, P < 0.01). It ameliorated both parenchymal and fatty tissue necrosis of the pancreas. Infliximab also alleviated alveolar edema and acute respiratory distress syndrome like pulmonary complications, but the difference was not significant.
Chimeric TNF antibody, infliximab, should be evaluated for treatment of acute pancreatitis.</abstract><cop>United States</cop><pmid>14707742</pmid><doi>10.1097/00006676-200401000-00020</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3177 |
| ispartof | Pancreas, 2004-01, Vol.28 (1), p.e1-e8 |
| issn | 0885-3177 1536-4828 |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00006676_200401000_00020 |
| source | MEDLINE; Journals@Ovid Ovid Autoload |
| subjects | Acute Disease Amylases - blood Animals Antibodies, Monoclonal - therapeutic use Ceruletide Edema - chemically induced Edema - drug therapy Infliximab Male Necrosis Pancreas - drug effects Pancreas - metabolism Pancreas - pathology Pancreatitis - chemically induced Pancreatitis - drug therapy Pancreatitis - pathology Pancreatitis, Acute Necrotizing - chemically induced Pancreatitis, Acute Necrotizing - drug therapy Pancreatitis, Acute Necrotizing - pathology Peroxidase - metabolism Pulmonary Edema - pathology Pulmonary Edema - prevention & control Rats Rats, Wistar Severity of Illness Index Taurocholic Acid Treatment Outcome Tumor Necrosis Factor-alpha - therapeutic use |
| title | Infliximab: a new therapeutic agent in acute pancreatitis? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T09%3A56%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infliximab:%20a%20new%20therapeutic%20agent%20in%20acute%20pancreatitis?&rft.jtitle=Pancreas&rft.au=Oruc,%20Nevin&rft.date=2004-01&rft.volume=28&rft.issue=1&rft.spage=e1&rft.epage=e8&rft.pages=e1-e8&rft.issn=0885-3177&rft.eissn=1536-4828&rft_id=info:doi/10.1097/00006676-200401000-00020&rft_dat=%3Cpubmed_cross%3E14707742%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/14707742&rfr_iscdi=true |